ACG Clinical Guideline: Alcoholic Liver Disease
- PMID: 29336434
- PMCID: PMC6524956
- DOI: 10.1038/ajg.2017.469
ACG Clinical Guideline: Alcoholic Liver Disease
Abstract
Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.
Conflict of interest statement
CONFLICT OF INTEREST
Figures
Comment in
-
ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established.Am J Gastroenterol. 2019 Jan;114(1):175-176. doi: 10.1038/s41395-018-0076-x. Am J Gastroenterol. 2019. PMID: 29887598 No abstract available.
-
Response to Forrest et al.Am J Gastroenterol. 2019 Jan;114(1):176. doi: 10.14309/ajg.0000000000000073. Am J Gastroenterol. 2019. PMID: 30633036 No abstract available.
Similar articles
-
ACG Clinical Guideline: Alcohol-Associated Liver Disease.Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. Am J Gastroenterol. 2024. PMID: 38174913
-
Therapy for alcoholic liver disease.World J Gastroenterol. 2014 Mar 7;20(9):2143-58. doi: 10.3748/wjg.v20.i9.2143. World J Gastroenterol. 2014. PMID: 24605013 Free PMC article. Review.
-
Recent updates on alcoholic hepatitis.Dig Liver Dis. 2019 Jun;51(6):761-768. doi: 10.1016/j.dld.2019.03.023. Epub 2019 Apr 19. Dig Liver Dis. 2019. PMID: 31010745 Review.
-
Diagnosis and management of alcoholic liver disease.J Dig Dis. 2011 Aug;12(4):257-62. doi: 10.1111/j.1751-2980.2010.00470.x. J Dig Dis. 2011. PMID: 21091932 Review.
-
Alcoholic Hepatitis: The Rising Epidemic.Med Clin North Am. 2023 May;107(3):533-554. doi: 10.1016/j.mcna.2022.12.005. Epub 2023 Feb 20. Med Clin North Am. 2023. PMID: 37001952 Review.
Cited by
-
ASPP2 deficiency attenuates lipid accumulation through the PPARγ pathway in alcoholic liver injury.Cell Biol Toxicol. 2024 Nov 22;40(1):102. doi: 10.1007/s10565-024-09925-x. Cell Biol Toxicol. 2024. PMID: 39576443 Free PMC article.
-
Alcohol-Associated Hepatitis: Short- and Long-Term Management.Dig Dis Sci. 2024 Nov 22. doi: 10.1007/s10620-024-08705-1. Online ahead of print. Dig Dis Sci. 2024. PMID: 39576428 Review.
-
Saikogenin A improves ethanol-induced liver injury by targeting SIRT1 to modulate lipid metabolism.Commun Biol. 2024 Nov 21;7(1):1547. doi: 10.1038/s42003-024-07234-x. Commun Biol. 2024. PMID: 39572758 Free PMC article.
-
Deciphering the role of LncRNA in alcoholic liver disease: Mechanisms and therapeutic potential.Medicine (Baltimore). 2024 Nov 8;103(45):e40378. doi: 10.1097/MD.0000000000040378. Medicine (Baltimore). 2024. PMID: 39533619 Free PMC article. Review.
-
Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease.World J Gastroenterol. 2024 Oct 28;30(40):4393-4398. doi: 10.3748/wjg.v30.i40.4393. World J Gastroenterol. 2024. PMID: 39494094 Free PMC article. Review.
References
-
- Yoon Y-H, Chen CM. Surveillance Report #105. Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000–2013. 2016. (cited 19 April 2017). Available at https://pubs.niaaa.nih.gov/publications/surveillance105/Cirr13.htm
-
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METaViR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825–32. - PubMed
-
- Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87–S96. - PubMed
-
- Orntoft NW, Sandahl TD, Jepsen P et al. Short-term and long-term causes of death in patients with alcoholic hepatitis in Denmark. Clin Gastroenterol Hepatol 2014;12:1739–44 e1. - PubMed
-
- Lackner C, Spindelboeck W, Haybaeck J et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol 2017; 66 : 610 – 8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
